HomeCompareFSMVX vs JNJ

FSMVX vs JNJ: Dividend Comparison 2026

FSMVX yields 7.82% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSMVX wins by $13.5K in total portfolio value
10 years
FSMVX
FSMVX
● Live price
7.82%
Share price
$30.61
Annual div
$2.39
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.6K
Annual income
$1,283.36
Full FSMVX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — FSMVX vs JNJ

📍 FSMVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSMVXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSMVX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSMVX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSMVX
Annual income on $10K today (after 15% tax)
$664.78/yr
After 10yr DRIP, annual income (after tax)
$1,090.86/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, FSMVX beats the other by $387.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSMVX + JNJ for your $10,000?

FSMVX: 50%JNJ: 50%
100% JNJ50/50100% FSMVX
Portfolio after 10yr
$26.8K
Annual income
$1,055.57/yr
Blended yield
3.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FSMVX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSMVX buys
0
JNJ buys
0
No recent congressional trades found for FSMVX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSMVXJNJ
Forward yield7.82%3.36%
Annual dividend / share$2.39$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$33.6K$20.0K
Annual income after 10y$1,283.36$827.78
Total dividends collected$10.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FSMVX vs JNJ ($10,000, DRIP)

YearFSMVX PortfolioFSMVX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,482$782.10$10,676$355.77+$806.00FSMVX
2$13,125$839.26$11,407$389.39+$1.7KFSMVX
3$14,940$896.59$12,198$426.53+$2.7KFSMVX
4$16,940$953.84$13,056$467.62+$3.9KFSMVX
5$19,137$1,010.75$13,987$513.12+$5.2KFSMVX
6$21,543$1,067.11$14,998$563.56+$6.5KFSMVX
7$24,174$1,122.72$16,098$619.52+$8.1KFSMVX
8$27,044$1,177.40$17,295$681.69+$9.7KFSMVX
9$30,168$1,231.00$18,599$750.82+$11.6KFSMVX
10$33,563$1,283.36$20,022$827.78+$13.5KFSMVX

FSMVX vs JNJ: Complete Analysis 2026

FSMVXStock

The fund normally invests at least 80% of its assets in securities of companies with medium market capitalizations (which, for purposes of this fund, are those companies with market capitalizations similar to companies in the Russell Midcap® Index or the S&P MidCap 400® Index). It invests in companies with smaller or larger market capitalizations. The fund invests in domestic and foreign issuers.

Full FSMVX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this FSMVX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSMVX vs SCHDFSMVX vs JEPIFSMVX vs OFSMVX vs KOFSMVX vs MAINFSMVX vs ABBVFSMVX vs MRKFSMVX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.